NASDAQ:CBIO - Catalyst Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.25 -0.05 (-0.49 %)
(As of 12/11/2018 11:13 AM ET)
Previous Close$10.30
Today's Range$10.25 - $10.40
52-Week Range$7.41 - $37.00
Volume806 shs
Average Volume135,606 shs
Market Capitalization$122.06 million
P/E Ratio-1.38
Dividend YieldN/A
Beta2.32
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing CB 2679d/ISU304, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company is headquartered in South San Francisco, California.

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CBIO
Previous Symbol
CUSIP87611R30
Phone650-266-8674

Debt

Debt-to-Equity RatioN/A
Current Ratio40.24
Quick Ratio40.24

Price-To-Earnings

Trailing P/E Ratio-1.38
Forward P/E Ratio-4.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.02 million
Price / Sales119.99
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.29 per share
Price / Book1.94

Profitability

EPS (Most Recent Fiscal Year)($7.45)
Net Income$-21,560,000.00
Net Margins-2,983.40%
Return on Equity-22.67%
Return on Assets-21.79%

Miscellaneous

Employees13
Outstanding Shares11,940,000
Market Cap$122.06 million
OptionableOptionable

Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences's stock reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences Inc (NASDAQ:CBIO) announced its quarterly earnings results on Friday, November, 2nd. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.05. Catalyst Biosciences had a negative return on equity of 22.67% and a negative net margin of 2,983.40%. View Catalyst Biosciences' Earnings History.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Catalyst Biosciences.

What price target have analysts set for CBIO?

2 equities research analysts have issued 12-month price objectives for Catalyst Biosciences' shares. Their forecasts range from $12.50 to $35.00. On average, they anticipate Catalyst Biosciences' stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 128.4% from the stock's current price. View Analyst Price Targets for Catalyst Biosciences.

What is the consensus analysts' recommendation for Catalyst Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Biosciences.

Has Catalyst Biosciences been receiving favorable news coverage?

Media stories about CBIO stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Biosciences earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Catalyst Biosciences' key competitors?

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the folowing people:
  • Dr. Nassim Usman, Pres, CEO & Director (Age 58)
  • Mr. Fletcher Payne, Chief Financial Officer (Age 55)
  • Dr. Howard Levy, Chief Medical Officer (Age 64)
  • Dr. Charles S. Craik, Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Nexthera Capital LP (7.48%), BlackRock Inc. (6.76%), Sio Capital Management LLC (4.61%), Marshall Wace LLP (4.59%), Renaissance Technologies LLC (3.69%) and Dimensional Fund Advisors LP (3.39%). Company insiders that own Catalyst Biosciences stock include Howard Levy and James E Flynn. View Institutional Ownership Trends for Catalyst Biosciences.

Which major investors are selling Catalyst Biosciences stock?

CBIO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtus ETF Advisers LLC and Marshall Wace LLP. Company insiders that have sold Catalyst Biosciences company stock in the last year include Howard Levy and James E Flynn. View Insider Buying and Selling for Catalyst Biosciences.

Which major investors are buying Catalyst Biosciences stock?

CBIO stock was acquired by a variety of institutional investors in the last quarter, including First Manhattan Co., Dimensional Fund Advisors LP, Prosight Management LP, GSA Capital Partners LLP, Nexthera Capital LP, Sio Capital Management LLC, AQR Capital Management LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Catalyst Biosciences.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $10.40.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $122.06 million and generates $1.02 million in revenue each year. The biopharmaceutical company earns $-21,560,000.00 in net income (profit) each year or ($7.45) on an earnings per share basis. Catalyst Biosciences employs 13 workers across the globe.

What is Catalyst Biosciences' official website?

The official website for Catalyst Biosciences is http://www.catalystbiosciences.com.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-8674 or via email at [email protected]


MarketBeat Community Rating for Catalyst Biosciences (NASDAQ CBIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Featured Article: Market Capitalization

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel